Abstract:Selection of the treatments most likely to combat a patient's tumor is a central aim of precision oncology. We are currently developing a functional precision oncology program at the University of Utah and Huntsman Cancer Institute that combines the multi-omic characterization of a patient's tumor with the functional screening of relevant drug candidates in patient-derived organoid tumor models to identify which drugs are uniquely capable of combating the patient's cancer. Here we present our model-based approach for utilizing the multi-omic tumor data to computationally predict the patient's response to each drug. In this approach, we first identify the genomic and transcriptomic vulnerabilities of the tumor as genes harboring somatic DNA mutations or copy number changes (from paired tumor/normal WGS/WES DNA sequencing data), as well as genes whose expression levels have been significantly altered in the tumor (based on bulk or single-cell RNA sequencing data). Second, using targeting information from drug-gene interaction databases (DGIdb) we compile a list of genes targeted by each drug relevant in the patient's treatment. Third, we utilize gene interaction database knowledge (KEGG) to construct a gene interaction graph to link each drug's gene targets with all of the tumor's vulnerability genes. We then identify all gene interaction paths connecting specific drug target genes with specific vulnerability genes; and score each path and combine all path-specific scores for the target-vulnerability gene pair. Subsequently, we further combine all pairwise scores across all drug target genes and all tumor vulnerability genes and determine the statistical significance of the resulting score by sampling the background distribution of such scores across random drugs, target genes, and vulnerability genes. We have applied our algorithm to predict drug response in advanced breast cancer patients as well as using publicly available tumor cell line data (GDSC2). We have found a high level of concordance between our computational prediction and organoid/cell line screening results, clearly separating sensitive and non-sensitive models. Using Bayesian probability, we compare the drug-specific score distributions of sensitive and non-sensitive models and are able to identify sensitive cell lines/patients with high accuracy. By encapsulating available information on direct gene-gene interactions, the drug's direct gene targets and the collected omic vulnerabilities of the tumor, our model is not only capable of predicting sensitivity to both targeted and chemotherapy agents, but can also provide a mechanistic understanding for the targeting of the tumor. Our approach will be validated and fine-tuned on a large cohort of breast and brain cancer patients as well as patient PDX models, interrogating gene-target interactions to identify novel relevant target genes/pathways. Citation Format: Szabolcs Tarapcsak, Yi Qiao, Xiaomeng Huang, Tony Di Sera, Matthew H. Bailey, Bryan E. Welm, Alana L. Welm, Gabor T. Marth. Model-based cancer therapy selection by linking tumor vulnerabilities to drug mechanism [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl) nr 2723.

Multivariate analysis of metabolic state vulnerabilities across diverse cancer contexts reveals synthetically lethal associations

Multivariate analysis of metabolic state vulnerabilities across diverse cancer contexts reveals synthetically lethal associations

Identification of Cancer–associated Metabolic Vulnerabilities by Modeling Multi-Objective Optimality in Metabolism

Computational modeling of cancer cell metabolism along the catabolic-anabolic axes

Pan-Cancer, Genome-Scale Metabolic Network Analysis of over 10,000 Patients Elucidates Relationship between Metabolism and Survival

Identifying Personalized Metabolic Signatures in Breast Cancer

Computational dissection of the regulatory mechanisms of aberrant metabolism in remodeling the microenvironment of breast cancer

Single cell atlas reveals multilayered metabolic heterogeneity across tumour types

Pinpointing Cancer Sub-Type Specific Metabolic Tasks Facilitates Identification of Anti-cancer Targets

Metabolic vulnerabilities in cancer: A new therapeutic strategy

A multilineage screen identifies actionable synthetic lethal interactions in human cancers

Integrated Metabolic Profiling and Transcriptional Analysis Reveals Therapeutic Modalities for Targeting Rapidly Proliferating Breast Cancers

Identification of metabolic vulnerabilities of receptor tyrosine kinases-driven cancer

Abstract 2723: Model-based cancer therapy selection by linking tumor vulnerabilities to drug mechanism

“Metabolic dysregulations of cancer cells with metastatic potential”

Elucidating cancer metabolic plasticity by coupling gene regulation with metabolic pathways

MMP3C: an in-silico framework to depict cancer metabolic plasticity using gene expression profiles

The Neglected Liaison: Targeting Cancer Cell Metabolic Reprogramming Modifies the Composition of Non-Malignant Populations of the Tumor Microenvironment

Characterization of the metabolic alteration-modulated tumor microenvironment mediated by TP53 mutation and hypoxia

Altered metabolism in cancer: insights into energy pathways and therapeutic targets

Bulk and single-cell transcriptome profiling reveal the metabolic heterogeneity in human breast cancers